Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 363 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Breastfeeding Duration Could Influence Breast Cancer Risk, Study Shows September 27, 2019 FDA Approves Pralsetinib for Lung Cancer with RET Gene Fusions September 10, 2020 April is Occupational Therapy (OT) Month- What is OT and how... April 8, 2021 Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of... March 11, 2025 Load more HOT NEWS Pattern of DNA Damage Links Colorectal Cancer and Diet High in... If You Let It, Nursing Will Change Your Life High Frequency of Germline ATM Variants in CLL What’s happened to cancer clinical trials during the COVID-19 pandemic?
